74C.F CROSSJECT SA EO -10

Healthcare Health Care Equipment & Supplies Frankfurt Exchange
1.34 EUR
Close of Nov 11, 2026
1.18 2.59
Market cap
EUR 81.1M
P/E
-
P/B
25.43x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 74C.F undervalued?

Graham number

The Graham number of CROSSJECT SA EO -10 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CROSSJECT SA EO -10 fundamental analysis

No fundamental analysis for CROSSJECT SA EO -10 yet.

CROSSJECT SA EO -10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CROSSJECT SA EO -10

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In additio…

Full company profile